# Notice of Intent - Sole Source for Pluvicto

Canonical: https://abierto.us/opportunities/36c26125q0797

- Solicitation number: 36C26125Q0797
- Notice type: Special notice
- Status: Closed. Deadline was September 19, 2025 at 12:00 PM EDT
- Department: Department of Veterans Affairs
- Contracting office: 261-Network Contract Office 21 (36C261)
- NAICS: 325412 Pharmaceutical Preparation Manufacturing
- Product or service code: 6505 Drugs and Biologicals
- Place of performance: Mather, California
- County: Sacramento County (FIPS 06067). https://abierto.us/counties/sacramento-county-ca-06067
- City: Mather. https://abierto.us/cities/mather-ca-0646226
- First posted: September 16, 2025
- Last posted: September 16, 2025
- SAM.gov: https://sam.gov/workspace/contract/opp/73720f27fac847c5aee959594aa5e8c6/view

## Description

Department of Veterans Affairs (VA), Regional Procurement Office West (RPOW), Network Contracting Office (NCO) 21, on behalf of Veterans Integrated Service Network (VISN) 21 intends to award a sole source, firm-fixed-price delivery order to Novartis Pharmaceuticals Corporation 59 Route 10, East Hanover, NJ 07936, for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). The associated North America Classification Systems (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing.

The VA Northern California Health Care System, 10535 Hospital Way, Mather, CA 95655, has a requirement for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) is a highly specialized radiopharmaceutical.

Pluvicto is a radiologic therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Per the FDA website https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Pluvicto is an FDA approved drug. Pluvicto manufactured and is a trademark of Novartis Pharmaceuticals Corporation.

This notice satisfies the requirement at FAR 5.201(b)(1), to publicize the proposed contract action. This notice of intent is not a request for competitive proposals. Interested parties may give written notice to victoria.torres@va.gov by 5:00pm PDT on 09/17/2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to meet the subject requirement. This information shall be provided at no cost or obligation to the Government.

Responses will be considered by the Government; however, a determination by the Government not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government. Inquiries shall be emailed to victoria.torres@va.gov. No telephone requests will be accepted. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government in future procurements.

## Publications

- September 16, 2025: Special notice, due September 19, 2025 at 12:00 PM EDT. Notice 73720f27fac847c5aee959594aa5e8c6. https://sam.gov/workspace/contract/opp/73720f27fac847c5aee959594aa5e8c6/view

## Points of contact

- VICTORIA TORRES, VICTORIA.TORRES@VA.GOV

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/36c26125q0797.